# Arthrosi Therapeutics

> Arthrosi Therapeutics, Inc. is a late-stage clinical biotechnology company founded in 2018
> and headquartered in San Diego, California. Its lead candidate, pozdeutinurad (AR882), is a
> once-daily oral next-generation URAT1 inhibitor in two fully enrolled replicate global Phase 3
> trials (REDUCE 1 and REDUCE 2) for progressive and tophaceous gout. Sobi (Swedish Orphan
> Biovitrum) completed its acquisition of Arthrosi on 9 February 2026.
>
> Arthrosi publishes NO public web API. There is no developer portal, no OpenAPI, no GraphQL
> endpoint, no AsyncAPI, no webhooks, no SDK or package on any registry, no MCP server and no
> A2A agent card. Arthrosi is a drug developer, not a software company; its only public digital
> surface is a WordPress corporate marketing site.
>
> Generated by API Evangelist from public sources on 2026-08-06. This is a third-party profile;
> API Evangelist does not operate Arthrosi Therapeutics software.

## Company

- [Website](https://arthrosi.com/): Company site. Note: every path on this host — including
  /robots.txt and a bogus control path — answers HTTP 202 with a SiteGround `sgcaptcha`
  interstitial, so automated clients cannot read any page of it.
- [About](https://arthrosi.com/company/): Company overview, San Diego, founded 2018.
- [Leadership team](https://arthrosi.com/team/)
- [News & media](https://arthrosi.com/news-media/): Press releases (Series D, Series E,
  Phase 3 REDUCE dosing, China joint venture, Sobi acquisition).
- [LinkedIn](https://www.linkedin.com/company/arthrosi-therapeutics-inc)
- [Forge Global secondary-market listing](https://forgeglobal.com/arthrosi-therapeutics_stock/)

## Pipeline

- Pozdeutinurad (AR882) — oral selective URAT1 inhibitor for gout and tophaceous gout;
  two fully enrolled replicate Phase 3 trials, REDUCE 1 and REDUCE 2, pivotal data expected 2026.
- Registered clinical-trial records for AR882 are published by the sponsor on
  ClinicalTrials.gov, which is a third-party US National Library of Medicine service, not an
  Arthrosi API.

## Developer surface

There is none. Probed and confirmed on 2026-08-06:

- No `api.`, `docs.`, `developer.`, `developers.`, `portal.` or `app.` subdomain resolves in DNS.
- No GitHub organization (`github.com/arthrosi` → 404); no first-party repositories.
- No packages on npm, PyPI, or any other registry.
- No `/llms.txt`, `/openapi.json`, `/swagger.json`, `/api-docs`, or `/.well-known/*` document —
  every request is answered by the bot-challenge interstitial rather than a document.

## API Evangelist artifacts

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/arthrosi-therapeutics/refs/heads/main/apis.yml)
- [Domain security](https://raw.githubusercontent.com/api-evangelist/arthrosi-therapeutics/refs/heads/main/security/arthrosi-therapeutics-domain-security.yml)
- [Well-known probe record](https://raw.githubusercontent.com/api-evangelist/arthrosi-therapeutics/refs/heads/main/well-known/arthrosi-therapeutics-well-known.yml)

## Optional

- Email domain is Microsoft 365 (`arthrosi-com.mail.protection.outlook.com`) with SPF and a
  DMARC policy of `quarantine`; no DNSSEC and no CAA records on arthrosi.com.
- Corporate contact address published in DMARC reporting: support@arthrosi.com